<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113033</url>
  </required_header>
  <id_info>
    <org_study_id>NVNS01</org_study_id>
    <nct_id>NCT02113033</nct_id>
  </id_info>
  <brief_title>VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients</brief_title>
  <acronym>VANGUARD</acronym>
  <official_title>VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for
      the treatment of congestive heart failure with reduced ejection fraction, and to report
      secondary measures of efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2014</start_date>
  <completion_date type="Actual">September 20, 2016</completion_date>
  <primary_completion_date type="Actual">February 22, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Equilia VNS device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the freedom from Serious Adverse Device Effects, defined as the number of patients without SADEs.</measure>
    <time_frame>6 Months</time_frame>
    <description>Adverse device effects will be sub-classified into device-related or procedure-related, when the adverse event has a generic cause independent from the device itself and occurs within 30 days of the implant procedure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Treated with Equilia system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Equilia® Vagal Nerve Stimulation</intervention_name>
    <description>Vagal Nerve Stimulation synchronized with cardiac activity</description>
    <arm_group_label>Treated with Equilia system</arm_group_label>
    <other_name>Device used: Equilia®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Left ventricular dysfunction of ischemic or idiopathic dilated cardiomyopathy
             etiology, characterized by LVEF &lt; 40%

          2. Chronic heart failure with symptoms characterized by NYHA functional class II or III
             at the time of enrollment despite optimal drug regimen

          3. Optimal drug regimen as defined in the current European guidelines

          4. Sinus rhythm, with spontaneous heart rate ≥ 60bpm at the time of enrollment

          5. Signed and dated informed consent

        Main Exclusion Criteria:

          -  Patient implanted with or eligible to cardiac pacing as per current guideline

          -  Risk for neck surgery in the electrode zone within a year after enrollment

          -  Patient with right carotid artery stenosis

          -  Symptomatic hypotension

          -  History of peptic ulcer disease or upper gastrointestinal bleeding

          -  Asthma, severe COPD, or severe restrictive lung disease

          -  Advanced Diabetes Mellitus

          -  Recent acute myocardial infarction, coronary artery surgery or revascularization (or
             already planned)

          -  Recent cerebro-vascular event

          -  Significant valvulopathy

          -  Advanced Renal failure

          -  Previous heart transplant or current LVAD device therapy

          -  Life expectancy &lt; 1 year for non-cardiac cause

          -  Patient included in another clinical study that could confound the results of this
             study

          -  Inability to understand the purpose of the study or to perform the procedures of the
             study

          -  Unavailability for scheduled follow-up

          -  Age of less than 18 years or under guardianship

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Hagege, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HEGP - Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL St Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dedinje Cardiovascular Institute</name>
      <address>
        <city>Belgrade</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Norway</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

